post-cal model adjust decreas ep estim
updat model follow thursday morn releas fiscal
second-quart earn decreas fiscal ep estim
midpoint compani updat guidanc addit decreas
ep estim follow addit clariti around impact
tax reform manag increas guidanc midpoint
result better tax rate due tax legisl chang
take-away commentari appear stabl
macro environ pharmaceut distribut businessa reassur sign
follow much higher degre turmoil normal past two year manag
indic brand inflat gener deflat within realm expect
maintain expect pharmaceut segment growth full year
convers medic segment remain difficult gaug given number move
piec present maintain market perform rate
encourag sign stabil estim competit pressur
pharmaceut segment pharmaceut segment revenu
quarter estim oper incom also less expect
declin compar declin estim fiscal compani
continu estim midsingle-digit gener deflat note includ
sell-sid gener pressur potenti benefit red oak sourc given
manag competitor commentari earn season believ risk
sell-sid price deterior abat somewhat believ gener deflat
pressur larg reflect fiscal guidanc model
oper incom growth
return equiti ttm
one largest healthcar distributor unit state canada strong market
share posit pharmaceut medic product distribut market cardin one three largest
player pharmaceut distribut market signific distributor medic consum suppli
hospit physician offic altern care site
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
medic segment medic segment slightli revenu estim quarter revenu
compar estim oper incom though compar growth target
given strong growth medtron patient recoveri asset contribut new exist custom
commentari latest purchas outlook gener construct segment profit primarili driven
compani acquisit somewhat off-set wors perform cardin brand product includ
cordi expect roughli organ revenu growth medic segmentdown previous
supplement patient recoveri acquisit
lower fiscal adjust ep estim model top-lin growth
consolid revenu growth previous result earlier-than-expect divestitur cardin china
busi pharmaceut segment reduc organ growth estim
medic segment reduc organ growth estim model fiscal
revenu billion billion maintain oper margin estim
lower fiscal ep estim increas revenu growth estim
given earlier expect divestitur maintain oper margin estim
model ep growth rate
valuat stock thought
thursday close trade time updat calendar ep estim
three turn five-year averag time slightli peer group averag time
maintain market perform rate await sign medic segment becom
consist organ contributor growth encourag sign greater stabil pharmaceut
segment updat model segment assumpt follow exhibit
good gross oper interest expens pre-tax incom tax net incom excl nonrecur item net earn attribut non-controlling incom cardin excl nonrecur excl tax item net net incom includ nonrec discontinu incom includ nonrec discontinu ep excl non-recurring item amort begin fy excl non-recurring item includ incl nonrec item amort excl non-recurring item amort beg averag share outstand analysi gross incom incom rate total incom incom excl non-recurring includ excl non-recurring amort beg fy share blair compani estimatesourc compani report william blair compani llc estim william blair
y/i metro growthorgan y/i growth profit million adjust amort begin fy y/i segment total oper y/i patient y/i growth profit million adjust amort begin fy y/i segment oper profit blair compani estimatesourc compani report william blair compani llc estim import disclosur
